Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

REGENXBIO Inc. - Common Stock (NQ:RGNX)

8.280 -0.180 (-2.13%)
Streaming Delayed Price Updated: 3:25 PM EDT, Mar 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 379,297
Open 8.250
Bid (Size) 8.270 (500)
Ask (Size) 8.280 (200)
Prev. Close 8.460
Today's Range 8.205 - 8.780
52wk Range 5.035 - 16.19
Shares Outstanding 43,466,186
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
On March 25, 2026, the landscape of neurodegenerative medicine underwent a seismic shift. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics (NASDAQ: DNLI)... 
Via Finterra
Topics Economy Initial Public Offering
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX
From Pomerantz LLP
Via GlobeNewswire

Performance

YTD
-39.0%
-39.0%
1 Month
+4.3%
+4.3%
3 Month
-42.7%
-42.7%
6 Month
-13.2%
-13.2%
1 Year
+0.9%
+0.9%

More News

Read More
News headline image
RGNX's Inadequate Risk Disclosures Allegedly Cost Investors $2.40/Share: Levi & Korsinsky, LLP
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
RGNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
REGENXBIO, Inc. Stockholders Should Contact Robbins LLP for Information About Leading the RGNX Class Action
From Robbins LLP
Via Business Wire
News headline image
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
RGNX DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Stephen Pakola Oversaw RGX-111 Safety Claims That Cost RGNX Investors Millions: Levi & Korsinsky, LLP
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
ROSEN, LEADING TRIAL ATTORNEYS, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
RGNX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Regenxbio Says Its Gene Therapy For Muscle Disorder Showed No Evidence Of Liver Injury In Study ↗
Via Stocktwits
Topics Death
News headline image
RGNX's Inadequate Risk Disclosures Allegedly Cost Investors $2.40/Share: Levi & Korsinsky, LLP
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX
From Pomerantz LLP
Via GlobeNewswire
News headline image
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
ROSEN, LEADING INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RGNX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
REGENXBIO (RGNX) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings

Frequently Asked Questions

Is REGENXBIO Inc. - Common Stock publicly traded?
Yes, REGENXBIO Inc. - Common Stock is publicly traded.
What exchange does REGENXBIO Inc. - Common Stock trade on?
REGENXBIO Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for REGENXBIO Inc. - Common Stock?
The ticker symbol for REGENXBIO Inc. - Common Stock is RGNX on the Nasdaq Stock Market
What is the current price of REGENXBIO Inc. - Common Stock?
The current price of REGENXBIO Inc. - Common Stock is 8.280
When was REGENXBIO Inc. - Common Stock last traded?
The last trade of REGENXBIO Inc. - Common Stock was at 03/26/26 03:25 PM ET
What is the market capitalization of REGENXBIO Inc. - Common Stock?
The market capitalization of REGENXBIO Inc. - Common Stock is 359.90M
How many shares of REGENXBIO Inc. - Common Stock are outstanding?
REGENXBIO Inc. - Common Stock has 360M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.